Search Results - "Mpindi, John P."

Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors by Kolberg, Matthias, Bruun, Jarle, Murumägi, Astrid, Mpindi, John P., Bergsland, Christian H., Høland, Maren, Eilertsen, Ina A., Danielsen, Stine A., Kallioniemi, Olli, Lothe, Ragnhild A.

“…Patients with malignant peripheral nerve sheath tumor (MPNST), a rare soft tissue cancer associated with loss of the tumor suppressor neurofibromin (NF1), have…”
Get full text

A novel transcript, VNN1‐AB, as a biomarker for colorectal cancer by Løvf, Marthe, Nome, Torfinn, Bruun, Jarle, Eknæs, Mette, Bakken, Anne C., Mpindi, John P., Kilpinen, Sami, Rognum, Torleiv O., Nesbakken, Arild, Kallioniemi, Olli, Lothe, Ragnhild A., Skotheim, Rolf I.

“…Colorectal cancer is a global health challenge with high incidence rate and mortality. The patients' prognosis is strongly associated with disease stage and…”
Get full text

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors by Pietarinen, Paavo O, Eide, Christopher A, Ayuda-Durán, Pilar, Potdar, Swapnil, Kuusanmäki, Heikki, Andersson, Emma I, Mpindi, John P, Pemovska, Tea, Kontro, Mika, Heckman, Caroline A, Kallioniemi, Olli, Wennerberg, Krister, Hjorth-Hansen, Henrik, Druker, Brian J, Enserink, Jorrit M, Tyner, Jeffrey W, Mustjoki, Satu, Porkka, Kimmo

“…Tyrosine kinase inhibitors (TKI) are the mainstay treatment of BCR-ABL1-positive leukemia and virtually all patients with chronic myeloid leukemia in chronic…”
Get full text

Drug sensitivity and resistance testing identifies PLK 1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors by Kolberg, Matthias, Bruun, Jarle, Murumägi, Astrid, Mpindi, John P., Bergsland, Christian H., Høland, Maren, Eilertsen, Ina A., Danielsen, Stine A., Kallioniemi, Olli, Lothe, Ragnhild A.

“…Patients with malignant peripheral nerve sheath tumor ( MPNST ), a rare soft tissue cancer associated with loss of the tumor suppressor neurofibromin ( NF 1),…”
Get full text

Comprehensive data-driven analysis of the impact of chemoinformatic structure on the genome-wide biological response profiles of cancer cells to 1159 drugs by Khan, Suleiman A, Faisal, Ali, Mpindi, John Patrick, Parkkinen, Juuso A, Kalliokoski, Tuomo, Poso, Antti, Kallioniemi, Olli P, Wennerberg, Krister, Kaski, Samuel

“…Detailed and systematic understanding of the biological effects of millions of available compounds on living cells is a significant challenge. As most…”
Get full text

Abstract 895: Quantitative drug sensitivity and resistance testing (DSRT) of primary ex vivo AML blasts highlights mTOR and MEK as potential key molecular driver signals of therapeutic significance by Pemovska, Tea, Kylesskiy, Evgeny, Kontro, Mika, Szwajda, Agnieszka, Karjalainen, Riikka, Majumder, Muntasir M., Malani, Disha, Bespalov, Maxim M., Eldfors, Samuli, Elonen, Erkki, Knowles, Jonathan, Murumägi, Astrid, Mpindi, John P., Edgren, Henrik, Venkata, Naga Poojitha Kota, Turunen, Laura, Mustjoki, Satu, Wolf, Maija, Yadav, Bhagwan, Aittokallio, Tero, Heckman, Caroline A., Porkka, Kimmo, Kallioniemi, Olli, Wennerberg, Krister

“…Abstract Identification of signaling pathways that are required for the growth and differentiation block of cells from adult acute myeloid leukemia (AML) is…”
Get full text